|
May 1, 2023
|
Caribou Biosciences to Participate in Upcoming Investor Conferences
|
|
|
April 17, 2023
|
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
|
|
|
April 4, 2023
|
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
|
|
|
March 29, 2023
|
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
|
|
|
March 29, 2023
|
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
|
|
|
March 9, 2023
|
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
|
|
|
March 8, 2023
|
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
|
|
|
February 1, 2023
|
Caribou Biosciences to Participate in Upcoming Investor Conferences
|
|
|
January 3, 2023
|
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
|
|
